• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Facebook
  • Instagram
  • LinkedIn
  • TikTok
  • Twitter
  • YouTube
CDE Almería – Centro de Documentación Europea – Universidad de Almería

CDE Almería - Centro de Documentación Europea - Universidad de Almería

Centro de Documentación Europea de la Universidad de Almería

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact
  • Spanish
  • English

HORIZON EUROPE: Emerging Technologies in Cell and Gene therapy

Inicio » EU Calls and Awards » Horizon Europe » Excellent Science » HORIZON EUROPE: Emerging Technologies in Cell and Gene therapy

2 de July de 2021

Scope

Cell and gene therapy (CGT) are widely accepted as top biomedical trends for over three years now and continue to evolve in their use for treating human diseases. CGTs are expected to increasingly shape the medical treatment and diagnosis, as we are approaching the era of precision medicine. Cell-based therapy is a promising strategy for effective treatment across a wide range of diseases though the focus so far, has primarily been on cancer, e.g. Chimeric Antigen Receptor T-cell (CAR-T) therapy made from removing T cells from individual patients, engineer them to be able to recognize and kill cancer cells before re-administer them to the same patient. CAR-T cell therapy is widely regarded as having revolutionised the treatment of some blood cancers. Recent research evidence suggests that cell therapy can effectively apply to solid cancers as well.

Gene therapy, on the other hand, is yet far from having revealed its full potential and, therefore, innovative gene therapies remain a top priority in genomic medicine. Some companies believe that, after having achieved a robust proof-of-concept, clinical development and downstream interaction with regulatory agencies will be easy. The reality, however, is that the whole process from concept to commercialisation, from research to commercial grade viral vector under GMP standards, is a very demanding one, with the constant need for technological improvements to successfully overcome challenges such as increasing accuracy/specificity and scaling up the production or the release of tests that must be completed before use in patients. Finally, combined cell- and gene-based approaches in preclinical studies, is a relatively new bio-trend that is increasingly gaining the interest of cell and gene therapy scientists worldwide.

With this Pathfinder Challenge, EIC strategically aims at reinforcing critical components of the European cell and gene therapy community, such as focused research consortia, start-ups and spinoffs, in their ability to compete and sustain in this fiercely competitive field, full of challenges and obstacles all along the way from discovery to the manufacturing step. Proposals submitted to this call should effectively address exactly that, by proposing convincing technological solutions and/or new breakthrough concepts that go far beyond the current state-of-the-art.

Proposers are invited to submit disease-specific or non-disease-specific proposals, focused on emerging technologies or technological solutions aimed to overcome the current cell and gene therapy challenges in one or several the areas listed below, but without being restricted only to these areas.

  • Advancing cell therapy manufacturing and products to a clinical stage
  • Improving adoptive cell therapies (CAR-T, TCR, TIL)
  • Identifying next generation cell therapies for cancer
  • Applying cell therapy to treat cancer patients in a personalised manner
  • Improving the effectiveness and lowering the risks of gene delivery systems (vectors)
  • Improving gene therapy manufacturing processes and production

Deadline

27 October 2021

More information

Horizon Europe – Call

Publicaciones relacionadas:

Seminar 'Research in Europe'Horizon Europe: ERC STARTING GRANTS Horizon Europe: Strategic Digital and Health Technologies Horizon: Research infrastructure services for rapid research responses to COVID-19 and other infectious disease epidemics Horizon Europe: Medical Technology and Devices: from Lab to Patient HORIZON EUROPE: Enhancing synergies between the EIC and Startup Europe

“This is a space for debate. All comments, for or against publication, that are respectful and do not contain expressions that are discriminatory, defamatory or contrary to current legislation will be published”.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Publicaciones relacionadas

Seminar 'Research in Europe'Horizon Europe: ERC STARTING GRANTS Horizon Europe: Strategic Digital and Health Technologies Horizon: Research infrastructure services for rapid research responses to COVID-19 and other infectious disease epidemics Horizon Europe: Medical Technology and Devices: from Lab to Patient HORIZON EUROPE: Enhancing synergies between the EIC and Startup Europe

Footer

Logotipo en negativo del Centro de Documentación Europea de Almería
  • CDE Almería
  • Edificio Parque Científico-Tecnológico (Pita)
  • Planta: 1ª, Despacho: 2904120.
  • Ctra. Sacramento s/n. Almería (Spain)
  • Teléfono: (+34) 950 015266

HOME
NEWS
DOCUMENTATION
EUROPE ON THE NET
ABOUT US

  • LEGAL NOTICE
  • PRIVACY POLICY
  • COOKIE POLICY
  • ACCESSIBILITY
  • SITEMAP

Copyright © 2023 CDE Almería · Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

<p>El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. ajustes</p>

Politica de privacidad

El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. <a href="/politica-de-cookies" rel="noopener" target="_blank">Más información</a>

Cookies estrictamente necesarias

Las cookies estrictamente necesarias tiene que activarse siempre para que podamos guardar tus preferencias de ajustes de cookies.

Básicamente la web no funcionara bien si no las activas.

Estas cookies son:

  • Comprobación de inicio de sesión.
  • Cookies de seguridad.
  • Aceptación/rechazo previo de cookies.

Si desactivas esta cookie no podremos guardar tus preferencias. Esto significa que cada vez que visites esta web tendrás que activar o desactivar las cookies de nuevo.

Cookies de terceros

Esta web utiliza Google Analytics, Google Tag Manager y Yandex Metrika para recopilar información anónima tal como el número de visitantes del sitio, o las páginas más populares.

Dejar estas cookies activas nos permite mejorar nuestra web.

¡Por favor, activa primero las cookies estrictamente necesarias para que podamos guardar tus preferencias!

Política de cookies

Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. Más información